Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113118
Chunk: 12

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 12
---
 as amended from time to time.

“Series D Preferred Stock”
refers to the Series D convertible preferred stock, $0.0001 par value per share, of CERo.

“Series E Certificate of Designations”
refers to the Certificate of Designations of Rights and Preferences of the Series E Preferred Stock, as amended from time to time.

“Series E Preferred Stock”
refers to the Series E convertible preferred stock, $0.0001 par value per share, of CERo.

“Sponsor” refers
to Phoenix Biotech Sponsor, LLC, a Delaware limited liability company.

“Tertiary Earnout Shares”
refer to the 500 shares of Common Stock issued to the holders of Legacy CERo common stock and Legacy CERo preferred stock in connection
with the Business Combination, which became fully vested upon the achievement of certain regulatory milestone-based earnout targets.

“Third PIPE Financing”
refers to the private placement pursuant to which we issued and sold, and certain investors purchased, shares of Series C Preferred Stock,
on the terms and conditions set forth in the Third Securities Purchase Agreement.

“Third PIPE Registration Rights Agreement” refers to the Registration Rights Agreement, dated as of September 26, 2024, by and between CERo and certain investors.

“Third Securities Purchase Agreement” refers to the Securities Purchase Agreement, dated as of September 25, 2024, by and among CERo and certain investors,
pursuant to which CERo agreed to issue and sell 2,853 shares of Series C Preferred Stock and the Series C Warrants to purchase 4,088 shares
of Common Stock.

“Warrant Preferred Shares”
refer to the shares of Preferred Stock underlying the Preferred Warrants.

“Warrants” refer
to the Private Placement Warrants, the Series A Warrants, the Series C Warrants, the December 2024 Common Warrants,
the January 2025 Common Warrants, the Public Warrants, the February 2025 Common Warrants and the February 2025 Pre-Funded Warrants.

<div align='center'>viii

PART 1 - FINANCIAL INFORMATION</div>

Item 1. Financial Statements

<div align='center'>CERO THERAPEUTICS HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS</div>

| ASSETS                                                                                                                                                                                                                                          
 Current assets:                                                                                                                                                                                                                                 |     | September 30, 
 2025          
 (Unaudited)   |